Conclusion
PsA, pain, fatigue, enthesitis
DISEASE, ENTHESITIS
This post hoc analysis demonstrated greater improvements from baseline in enthesitis and disease activity measures in patients with PsA receiving tofacitinib vs placebo across several enthesitis locations and with varying enthesitis severity at baseline. An association between enthesitis at the lateral epicondyle humerus and Achilles tendon insertion and improvement in pain, and an association between enthesitis severity (assessed by SPARCC) and improvements in fatigue and pain were identified. These findings support tofacitinib as a treatment option for patients with PsA with enthesitis and affirm the importance of addressing enthesitis in the PsA treatment paradigm.